{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:28:00Z","timestamp":1786343280513,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but reliable peripheral blood biomarkers for monitoring treatment response and predicting prognosis remain limited. This study aimed to analyze the dynamic changes of lymphocyte subsets in patients receiving ICI therapy, evaluate their role in treatment response monitoring and prognosis assessment, and develop a practical clinical risk stratification tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 121 patients with malignancies who received ICI therapy and had available lymphocyte subset data were retrospectively enrolled. Peripheral blood lymphocyte subsets and routine blood test data were collected before and after treatment. The associations between changes in these parameters and treatment response as well as progression-free survival (PFS) were analyzed using univariate and multivariate Cox regression models. A risk score model and a simplified clinical scoring system were constructed and validated using time-dependent receiver operating characteristic (ROC) curves and Kaplan-Meier analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pan-cancer analysis showed that a decrease in CD8+ T cell count after treatment was significantly associated with progressive disease (PD) and inversely correlated with PFS (HR\u00a0=\u00a00.2308, 95% CI: 0.0875-0.5636). A non-immunotherapy validation cohort further confirmed the immunotherapy-specific nature of CD8+ T cell dynamics. Multivariate Cox analysis identified decreased CD8+ T cell count, elevated neutrophil-to-lymphocyte ratio (NLR), multiple lines of therapy, and specific cancer types (hepatopancreatobiliary malignancies) as independent unfavorable prognostic factors. Time-dependent area under the curve (AUC) values at 2.5, 3.5, and 5.7 months were 0.727, 0.827, and 0.853, respectively, indicating good predictive performance. The risk score based on these variables stratified patients into low-, medium-, and high-risk groups (median PFS: not reached, not reached, and 4.5 months, respectively; p&amp;lt;0.001). A simplified clinical scoring system also effectively distinguished different prognostic groups (median PFS: not reached, 6.2 months, and 4.3 months, respectively; p&amp;lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The dynamic change in CD8+ T cell count before and after treatment is an independent predictor of PFS in patients receiving ICI therapy and exhibits immunotherapy specificity. The proposed risk stratification tool, incorporating CD8+ T cell dynamics, NLR change, and key clinical variables, provides a simple and effective approach for prognostic assessment and may facilitate individualized treatment decision-making in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1870840","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:31:08Z","timestamp":1786339868000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A predictive model for immunotherapy efficacy in cancer based on dynamic changes of CD8+ T cells: a pan-cancer retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Mengyan","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Shanghai Key Laboratory of Gastric Neoplasms","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Jing","sequence":"additional","affiliation":[{"name":"Cancer Center, Daping Hospital & Army Medical Center of PLA, Third Military Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.cell.2023.02.039","article-title":"Advances in cancer immunotherapies","volume":"186","author":"Dagher","year":"2023","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","article-title":"Improved prediction of immune checkpoint blockade efficacy across multiple cancer types","volume":"40","author":"Chowell","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.002","article-title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians","volume":"31","author":"Subbiah","year":"2020","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01581-6","article-title":"Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency","volume":"28","author":"Das","year":"2022","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10555-025-10260-8","article-title":"Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly","volume":"44","author":"Adashek","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/08465371251355866","article-title":"iRECIST: A case based users guide for radiologists","volume":"77","author":"Waters","year":"2026","journal-title":"Can Assoc Radiol J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100706","article-title":"Sweet immune checkpoint targets to enhance T cell therapy","volume":"208","author":"Derosiers","year":"2022","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.14261","article-title":"The prognostic role of baseline and early dynamics of peripheral blood cell ratios in metastatic renal cell carcinoma patients treated with nivolumab","volume":"40","author":"Fiala","year":"2026","journal-title":"In Vivo"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102222","article-title":"Predicting response to PD-1 inhibitors in head and neck squamous cell carcinomas using peripheral blood inflammatory markers","volume":"51","author":"Fang","year":"2025","journal-title":"Transl Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-260","article-title":"Quantitative peripheral live single T-cell dynamic polyfunctionality profiling predicts lung cancer checkpoint immunotherapy treatment response and clinical outcomes","volume":"13","author":"Lim","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/jci180080","article-title":"Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy","volume":"134","author":"Zhou","year":"2024","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715234","article-title":"CD8(+) T cell exhaustion in cancer","volume":"12","author":"Dolina","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1738","article-title":"Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8(+) T-cell infiltration in hepatocellular carcinoma","volume":"14","author":"Song","year":"2024","journal-title":"Clin Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer-derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier","year":"2017","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-020-0379-4","article-title":"Establishment of patient-derived cancer organoids for drug-screening applications","volume":"15","author":"Driehuis","year":"2020","journal-title":"Nat Protoc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217821","article-title":"Role of artificial intelligence in cancer drug discovery and development","volume":"627","author":"Sarvepalli","year":"2025","journal-title":"Cancer Lett"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","article-title":"Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06217-y","article-title":"PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens","volume":"619","author":"Damo","year":"2023","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0628-3","article-title":"Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction","volume":"36","author":"Kunimasa","year":"2018","journal-title":"Invest New Drugs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007305","article-title":"Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.cmet.2025.11.016","article-title":"Uridine depletion impairs CD8+ T cell antitumor activity through N-glycosylation","volume":"38","author":"Xiao","year":"2026","journal-title":"Cell Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ccell.2024.12.001","article-title":"Targeting P4HA1 promotes CD8(+) T cell progenitor expansion toward immune memory and systemic anti-tumor immunity","volume":"43","author":"Ma","year":"2025","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-22-0851","article-title":"Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T-cell and activated treg compartment","volume":"13","author":"van der Leun","year":"2023","journal-title":"Cancer Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1870840\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:31:09Z","timestamp":1786339869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1870840\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1870840"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1870840","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1870840"}}